PerkinElmer, Inc.
Mar 30, 2011
PDF

PerkinElmer’s ViaCord® Family Cord Blood Banking Business Announces First and Only Service to Bank Stem Cells Harvested from Umbilical Cord Tissue

WALTHAM, MA –PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that its family cord blood banking business, ViaCord®, will now offer expectant parents umbilical cord tissue stem cell banking services. This latest addition to the ViaCord portfolio complements its cord blood banking service.

Umbilical cord tissue is a rich source of mesenchymal stem cells (MSCs). Banking newborn cord tissue stem cells in addition to cord blood stem cells provides a greater number and variety of cells, so patients may increase their chances of potential success and benefit from possible therapeutic applications. Results from more than 50 preclinical studies involving MSCs extracted from cord tissue have been published, underscoring the potential treatment value of MSCs to the scientific and medical community. Published research has found that tissue-derived stem cells have been shown to offer potential treatment of disorders such as Parkinson’s, stroke, type 1 diabetes and sports injuries.

The new services are enabled through an exclusive licensing agreement with AuxoCell Laboratories, Inc., a leading stem cell therapeutic and regenerative medicine company. Under the terms of the license agreement, ViaCord’s customers are granted exclusive family banking access to Auxocell’s patent for expanding MSCs derived from umbilical cord tissue. Additionally, ViaCord uses Auxocell’s validated technology for processing and cryopreserving MSCs from umbilical cord tissue.

"Researchers in a preclinical study, presented by AuxoCell at the October 2010 meeting of the International Placenta Stem Cell Society, found that combining the stem cells from umbilical cord tissue with stem cells from cord blood results in improved engraftment – up to a six-times increase over cord blood alone," said Morey Kraus, ViaCord’s chief scientific officer. "ViaCord is excited to offer another source of stem cells to our customers.  In addition, our relationship with Auxocell allows us to provide our family banking customers with even greater confidence through deploying a validated method for processing these cells and exclusive access to expanding these cells."  

ViaCord family cord blood banking services currently offers expectant families the opportunity to preserve their baby’s umbilical cord blood for potential medical use by the child or a related family member. To date, ViaCord has preserved the umbilical cord blood of more than 250,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi’s anemia. Today there are nearly 80 diseases treatable with cord blood stem cells, including cancers, certain blood disorders and immunodeficiencies.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Media Contacts:

Amanda L. Connolly
Edelman (On behalf of PerkinElmer, Inc.)
Phone: (404) 832-6785
Email: amanda.connolly@edelman.com